Publication: Surgery Triggers Outgrowth of Latent Distant Disease in Breast Cancer: An Inconvenient Truth?
Open/View Files
Date
2010
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI Publishing
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Retsky, Michael, Romano Demicheli, William Hrushesky, Michael Baum and Isaac Gukas. 2010. Surgery triggers outgrowth of latent distant disease in breast cancer: An Inconvenient Truth? Cancers 2(2): 305-337.
Research Data
Abstract
We review our work over the past 14 years that began when we were first confronted with bimodal relapse patterns in two breast cancer databases from different countries. These data were unexplainable with the accepted continuous tumor growth paradigm. To explain these data, we proposed that metastatic breast cancer growth commonly includes periods of temporary dormancy at both the single cell phase and the avascular micrometastasis phase. We also suggested that surgery to remove the primary tumor often terminates dormancy resulting in accelerated relapses. These iatrogenic events are apparently very common in that over half of all metastatic relapses progress in that manner. Assuming this is true, there should be ample and clear evidence in clinical data. We review here the breast cancer paradigm from a variety of historical, clinical, and scientific perspectives and consider how dormancy and surgery-driven escape from dormancy would be observed and what this would mean. Dormancy can be identified in these diverse data but most conspicuous is the sudden synchronized escape from dormancy following primary surgery. On the basis of our findings, we suggest a new paradigm for early stage breast cancer. We also suggest a new treatment that is meant to stabilize and preserve dormancy rather than attempt to kill all cancer cells as is the present strategy.
Description
Other Available Sources
Keywords
breast cancer, dormancy, surgery induced growth, mammography, chemotherapy, primary antiangiogenic therapy
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service